Boston Scientific Corporation (BSX)
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Boston Scientific Corporation (BSX) Q1 2025 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX ) Q1 2025 Results Conference Call April 23, 2025 8:00 AM ET Company Participants Jon Monson - Senior Vice President, Investor Relations Mike Mahoney - Chairman and Chief Executive Officer Dan Brennan - Executive Vice President and Chief Financial Officer Ken Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Rick Wise - Stifel David Roman - Goldman Sachs Travis Steed - Bank of America Patrick Wood - Morgan Stanley Danielle Antalffy - UBS Josh Jennings - TD Cowen Michael Polark - Wolfe Research Vijay Kumar - Evercore ISI Matt Miksic - Barclays Operator Good morning, and welcome to the Boston Scientific First Quarter 2025 Earnings Call. All participants will be in listen-only mode.
BSX Q1 Earnings & Revenues Beat, Stock Up, 2025 View Raised
Boston Scientific's first-quarter 2025 performance benefits from the strength of its product portfolio.
Boston Scientific (BSX) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Boston Scientific Stock Surges on Strong Results, Outlook; CFO To Retire
Shares of Boston Scientific (BSX) rose sharply Wednesday after the firm posted first-quarter results that topped analysts' estimates.
Boston Scientific (BSX) Q1 Earnings and Revenues Top Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.56 per share a year ago.
Boston Scientific raises 2025 profit forecast on strong heart device sales
Boston Scientific raised its annual profit forecast after strong sales of its heart devices helped beat Wall Street expectations for first-quarter profit.
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Boston Scientific (BSX) closed at $95.12, marking a -0.14% move from the previous day.
Should You Buy Boston Scientific Stock Ahead of Q1 Earnings?
Banking on robust above-market growth across all business units, BSX is expected to have witnessed strong international momentum in the first quarter.
Boston Scientific (BSX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Boston Scientific (BSX) Ascends But Remains Behind Market: Some Facts to Note
In the latest trading session, Boston Scientific (BSX) closed at $93.67, marking a +1.11% move from the previous day.
Boston Scientific (BSX) Is Considered a Good Investment by Brokers: Is That True?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
